{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=5",
    "query": {
      "intervention": "cyclophosphamide",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 2801,
    "total_pages": 281,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclophosphamide&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T21:05:41.443Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00912223",
      "title": "Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "1 Year to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2009-04",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 21,
      "location_summary": "Duarte, California • La Jolla, California • Sacramento, California + 17 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912223"
    },
    {
      "nct_id": "NCT06400303",
      "title": "KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Systemic Sclerosis - Diffuse Cutaneous",
        "Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria"
      ],
      "interventions": [
        {
          "name": "KYV-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2024-08-06",
      "completion_date": "2026-06-16",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Great Neck, New York",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06400303"
    },
    {
      "nct_id": "NCT02162420",
      "title": "Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dyskeratosis Congenita",
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-thymocyte globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "0 Years to 70 Years"
      },
      "enrollment_count": 61,
      "start_date": "2015-01-10",
      "completion_date": "2025-03-11",
      "has_results": true,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02162420"
    },
    {
      "nct_id": "NCT03861403",
      "title": "A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Triple Negative Breast Cancer",
        "Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer",
        "Advanced Metastatic Castration-Resistant Prostate Cancer",
        "Advanced Platinum-Resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TRX518",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leap Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-05-20",
      "completion_date": "2020-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 4,
      "location_summary": "Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03861403"
    },
    {
      "nct_id": "NCT00512096",
      "title": "Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Penile Cancer"
      ],
      "interventions": [
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel (Taxol)",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "14 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "1999-08",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00512096"
    },
    {
      "nct_id": "NCT00113646",
      "title": "Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "MEDI-507",
          "type": "DRUG"
        },
        {
          "name": "Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2002-11",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2018-03-16",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113646"
    },
    {
      "nct_id": "NCT03670966",
      "title": "211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia in Remission",
        "Chronic Myelomonocytic Leukemia",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Hematopoietic and Lymphoid Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Granulocyte Colony-Stimulating Factor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-07-10",
      "completion_date": "2029-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03670966"
    },
    {
      "nct_id": "NCT06972069",
      "title": "Tolerance Through Mixed Chimerism (Sip-Tego)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Kidney Failure",
        "Transplant Recipient (Kidney)",
        "Transplant Tolerance",
        "Immunosuppresion",
        "Immunosuppression After Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Combined Kidney/Bone Marrow Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Donation of Kidney / Bone Marrow",
          "type": "PROCEDURE"
        },
        {
          "name": "Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Tatsuo Kawai, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2025-05-31",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06972069"
    },
    {
      "nct_id": "NCT01055496",
      "title": "Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone",
          "type": "DRUG"
        },
        {
          "name": "inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2010-03",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2019-08-02",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 10,
      "location_summary": "Gainesville, Florida • Philadelphia, Pennsylvania • Houston, Texas + 5 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01055496"
    },
    {
      "nct_id": "NCT03032783",
      "title": "A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Donor Lymphocyte Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2017-01-31",
      "completion_date": "2025-12-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-10-25T21:05:41.443Z",
      "location_count": 1,
      "location_summary": "Philadephia, Pennsylvania",
      "locations": [
        {
          "city": "Philadephia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03032783"
    }
  ]
}